Sumoylation at the Host-Pathogen Interface
Abstract
:1. Introduction–Pathogens and Host Systems
2. The SUMO System
Virus | Protein | Reference |
---|---|---|
Adenovirus (Ad) | E1B-55K | [127] |
Adeno-associated virus (AAV) | Rep 78 | [128] |
Cytomegalovirus (CMV) | IE1 | [108] |
IE2 | [116] | |
Epstein-Barr Virus (EBV) | Zta (BZLF1) | [105] |
Rta (FRLF1) | [132] | |
EBNA3C | [133] | |
Hepatitis Delta virus (HDV) | HDAg | [134] |
Human herpesvirus 6 (HHV6) | IE1B | [136,137] |
Human immunodeficiency virus (HIV) | p6 | [140] |
Integrase | [126] | |
Human T-cell leukemia virus (HTLV) | Tax | [129] |
Influenza | NS1 | [145] |
PB1, NP, M1, NS2 | [93] | |
Kaposi's sarcoma-associated herpesvirus (KSHV) | K-bZIP | [76] |
LANA2 | [106] | |
Moloney murine leukemia virus (MMLV) | CA | [130] |
Papillomavirus | E1 | [135] |
E2 | [138] | |
L2 | [91] | |
Parainfluenza virus 5 | P | [141] |
Picornavirus | EV71 3C | [142] |
Severe acute respiratory syndrome coronavirus (SARS-CoV) | N | [139] |
Vaccina virus | A40R | [143] |
E3 | [131] | |
Varicella-zoster virus (VZV) | ORF29p | [144] |
3. Sumoylation and Innate Immunity
4. Mechanisms of Pathogen Impact on Host Sumoylation
4.1. Pathogen Proteins that Mimic Sumoylation Enzymes
4.2. Pathogen Proteins that Act as STUbLs
4.3. Pathogen Proteins that Target Sumoylation Enzymes
4.4. Pathogen Proteins that Modulate Sumoylation of Specific Host SUMO Substrates
5. Conclusions
Acknowledgments
References
- Yaniv, M. Small DNA tumour viruses and their contributions to our understanding of transcription control. Virology 2009, 384, 369–374. [Google Scholar]
- Lazo, P.A.; Santos, C.R. Interference with p53 functions in human viral infections, a target for novel antiviral strategies? Rev. Med. Virol. 2011, 21, 285–300. [Google Scholar]
- Felsani, A.; Mileo, A.M.; Paggi, M.G. Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. Oncogene 2006, 25, 5277–5285. [Google Scholar]
- Isaacson, M.K.; Ploegh, H.L. Ubiquitination, ubiquitin-like modifiers, and deubiquitination in viral infection. Cell Host Microbe 2009, 5, 559–570. [Google Scholar] [CrossRef]
- Ohsumi, Y. Molecular dissection of autophagy: Two ubiquitin-like systems. Nat. Rev. Mol. Cell Biol. 2001, 2, 211–216. [Google Scholar]
- Kamitani, T.; Kito, K.; Nguyen, H.P.; Yeh, E.T. Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein. J. Biol. Chem. 1997, 272, 28557–28562. [Google Scholar]
- Loeb, K.R.; Haas, A.L. The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. J. Biol. Chem. 1992, 267, 7806–7813. [Google Scholar]
- Boddy, M.N.; Howe, K.; Etkin, L.D.; Solomon, E.; Freemont, P.S. Pic 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. Oncogene 1996, 13, 971–982. [Google Scholar]
- Matunis, M.J.; Coutavas, E.; Blobel, G. A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex. J. Cell Biol. 1996, 135, 1457–1470. [Google Scholar]
- Okura, T.; Gong, L.; Kamitani, T.; Wada, T.; Okura, I.; Wei, C.F.; Chang, H.M.; Yeh, E.T. Protection against Fas/Apo-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J. Immunol. 1996, 157, 4277–4281. [Google Scholar]
- Shen, Z.Y.; Pardingtonpurtymun, P.E.; Comeaux, J.C.; Moyzis, R.K.; Chen, D.J. Ubl1, a human ubiquitin-like protein associating with human Rad51/Rad52 proteins. Genomics 1996, 36, 271–279. [Google Scholar]
- Boggio, R.; Chiocca, S. Viruses and sumoylation: Recent highlights. Curr. Opin. Micro. 2006, 9, 430–436. [Google Scholar]
- Deyrieux, A.; Wilson, V.G. Viral Interplay with the Host Sumoylation System. In Sumo Regulation of Cellular Processes; Wilson, V.G., Ed.; Springer: Dordrecht, The Netherlands, 2009; pp. 315–329. [Google Scholar]
- Bekes, M.; Drag, M. Trojan horse strategies used by pathogens to influence the small ubiquitin-like modifier (SUMO) system of host eukaryotic cells. J. Innate Immun. 2012, 4, 159–167. [Google Scholar] [CrossRef]
- Melchior, F. SUMO - nonclassical ubiquitin. Ann. Rev. Cell Dev. Biol. 2000, 16, 591–626. [Google Scholar]
- Muller, S.; Hoege, C.; Pyrowolakis, G.; Jentsch, S. SUMO, ubiquitin’s mysterious cousin. Nat. Rev. Mol. Cell Biol. 2001, 2, 202–210. [Google Scholar]
- Saitoh, H.; Pu, R.T.; Dasso, M. SUMO-1: Wrestling with a new ubiquitin-related modifier. Trends Biochem. Sci. 1997, 22, 374–376. [Google Scholar]
- Lapenta, V.; Chiurazzi, P.; van der Spek, P.; Pizzuti, A.; Hanaoka, F.; Brahe, C. Smt3a, a human homologue of the s. Cerevisiae Smt3 gene, maps to chromosome 21qter and defines a novel gene family. Genomics 1997, 40, 362–366. [Google Scholar] [CrossRef]
- Bohren, K.M.; Nadkarni, V.; Song, J.H.; Gabbay, K.H.; Owerbach, D. A m55v polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type i diabetes mellitus. J. Biol. Chem. 2004, 279, 27233–27238. [Google Scholar]
- Wang, C.Y.; She, J.X. SUMO4 and its role in type 1 diabetes pathogenesis. Diabetes-Metab. Res. Rev. 2008, 24, 93–102. [Google Scholar]
- Desterro, J.M.; Thomson, J.; Hay, R.T. Ubc9 conjugates SUMO but not ubiquitin. FEBS Lett. 1997, 417, 297–300. [Google Scholar]
- Saitoh, H.; Sparrow, D.B.; Shiomi, T.; Pu, R.T.; Nishimoto, T.; Mohun, T.J.; Dasso, M. Ubc9p and the conjugation of SUMO-1 to RanGAP1 and RanBP2. Curr. Biol. 1998, 8, 121–124. [Google Scholar]
- Desterro, J.M.P.; Rodriguez, M.S.; Kemp, G.D.; Hay, R.T. Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1. J. Biol. Chem. 1999, 274, 10618–10624. [Google Scholar]
- Chakrabarti, S.R.; Sood, R.; Ganguly, S.; Bohlander, S.; Shen, Z.Y.; Nucifora, G. Modulation of Tel transcription activity by interaction with the ubiquitin-conjugating enzyme Ubc9. Proc. Natl. Acad. Sci. USA 1999, 96, 7467–7472. [Google Scholar]
- Hateboer, G.; Hijmans, E.M.; Nooij, J.B.; Schlenker, S.; Jentsch, S.; Bernards, R. MUbc9, a novel adenovirus E1A-interacting protein that complements a yeast cell cycle defect. J. Biol. Chem. 1996, 271, 25906–25911. [Google Scholar]
- Poukka, H.; Aarnisalo, P.; Karvonen, U.; Palvimo, J.J.; Janne, O.A. Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription. J. Biol. Chem. 1999, 274, 19441–19446. [Google Scholar]
- Takahashi, Y.; Kahyo, T.; Toh-e, A.; Yasuda, H.; Kikuchi, Y. Yeast ull1/siz1 is a novel SUMO1/Smt3 ligase for septin components and functions as an adaptor between conjugating enzyme and substrates. J. Biol. Chem. 2001, 276, 48973–48977. [Google Scholar]
- Takahashi, Y.; Toh-e, A.; Kikuchi, Y. A novel factor required for the SUMO1/Sm3 conjugation of yeast septins. Gene 2001, 275, 223–231. [Google Scholar]
- Sachdev, S.; Bruhn, L.; Sieber, H.; Pichler, A.; Melchior, F.; Grosschedl, R. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses lef1 activity by sequestration into nuclear bodie. Genes Dev. 2001, 15, 3088–3103. [Google Scholar] [CrossRef]
- Pichler, A.; Gast, A.; Seeler, J.S.; Dejean, A.; Melchior, F. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 2002, 108, 109–120. [Google Scholar]
- Kagey, M.H.; Melhuish, T.A.; Wotton, D. The polycomb protein Pc2 is a SUMO E3 ligase. Cell 2003, 113, 127–137. [Google Scholar]
- Weger, S.; Hammer, E.; Heilbronn, R. Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo. FEBS Lett. 2005, 579, 5007–5012. [Google Scholar] [CrossRef]
- Chu, Y.; Yang, X. SUMO E3 ligase activity of TRIM proteins. Oncogene 2011, 30, 1108–1116. [Google Scholar]
- Yeh, E.T.H. Sumoylation and de-sumoylation: Wrestling with life’s processes. J. Biol. Chem. 2009, 284, 8223–8227. [Google Scholar]
- Best, J.L.; Ganiatsas, S.; Agarwal, S.; Changou, A.; Salomoni, P.; Shirihai, O.; Meluh, P.B.; Pandolfi, P.P.; Zon, L.I. SUMO-1 protease-1 regulates gene transcription through PML. Mol. Cell 2002, 10, 843–855. [Google Scholar]
- Gong, L.M.; Millas, S.; Maul, G.G.; Yeh, E.T.H. Differential regulation of sentrinized proteins by a novel sentrin-specific protease. J. Biol. Chem. 2000, 275, 3355–3359. [Google Scholar]
- Nishida, T.; Kaneko, F.; Kitagawa, M.; Yasuda, H. Characterization of a novel mammalian SUMO-1/Smt3-specific isopeptidase, a homologue of rat Axam, which is an axin-binding protein promoting beta-catenin degradation. J. Biol. Chem. 2001, 276, 39060–39066. [Google Scholar]
- Kadoya, T.; Yamamoto, H.; Suzuki, T.; Yukita, A.; Fukui, A.; Michiue, T.; Asahara, T.; Tanaka, K.; Asashima, M.; Kikuchi, A. Desumoylation activity of Axam, a novel axin-binding protein, is involved in downregulation of beta-catenin. Mol. Cell. Biol. 2002, 22, 3803–3819. [Google Scholar] [CrossRef]
- Kim, K.I.; Baek, S.H.; Jeon, Y.J.; Nishimori, S.; Suzuki, T.; Uchida, S.; Shimbara, N.; Saitoh, H.; Tanaka, K.; Chung, C.H. A new SUMO-1-specific protease, Susp1, that is highly expressed in reproductive organs. J. Biol. Chem. 2000, 275, 14102–14106. [Google Scholar]
- Wilson, V.G. SUMO Regulation of Cellular Processes.; Springer: Dordrecht, The Netherlands, 2009; p. 339. [Google Scholar]
- Rajan, S.; Plant, L.D.; Rabin, M.L.; Butler, M.H.; Goldstein, S.A.N. Sumoylation silences the plasma membrane leak k+ channel K2p1. Cell 2005, 121, 37–47. [Google Scholar]
- Dai, X.Q.; Kolic, J.; Marchi, P.; Sipione, S.; MacDonald, P.E. Sumoylation regulates kv2.1 and modulates pancreatic beta-cell excitability. J. Cell. Sci. 2009, 122, 775–779. [Google Scholar]
- Makhnevych, T.; Sydorskyy, Y.; Xin, X.; Srikumar, T.; Vizeacoumar, F.J.; Jeram, S.M.; Li, Z.; Bahr, S.; Andrews, B.J.; Boone, C.; et al. Global map of SUMO function revealed by protein-protein interaction and genetic networks. Mol. Cell 2009, 33, 124–135. [Google Scholar] [CrossRef]
- Agbor, T.A.; Taylor, C.T. SUMO, hypoxia and the regulation of metabolism. Biochem. Soc. Trans. 2008, 36, 445–448. [Google Scholar]
- Wimmer, P.; Schreiner, S.; Dobner, T. Human pathogens and the host cell sumoylation system. J. Virol. 2012, 86, 642–654. [Google Scholar]
- Thompson, M.R.; Kaminski, J.J.; Kurt-Jones, E.A.; Fitzgerald, K.A. Pattern recognition receptors and the innate immune response to viral infection. Viruses 2011, 3, 920–940. [Google Scholar]
- Mi, Z.; Fu, J.; Xiong, Y.; Tang, H. Sumoylation of RIG-1 positively regulates the type I interferon signaling. Protein Cell 2010, 1, 275–283. [Google Scholar]
- Fu, J.H.; Xiong, Y.B.; Xu, Y.L.; Cheng, G.H.; Tang, H. Mda5 is sumoylated by PIAS2 beta in the upregulation of type i interferon signaling. Mol. Immunol. 2011, 48, 415–422. [Google Scholar]
- Kim, J.H.; Sung, K.S.; Jung, S.M.; Lee, Y.S.; Kwon, J.Y.; Choi, C.Y.; Park, S.H. Pellino-1, an adaptor protein of interleukin-1 receptor/toll-like receptor signaling, is sumoylated by Ubc9. Mol. Cells 2011, 31, 85–89. [Google Scholar] [CrossRef]
- Kubota, T.; Matsuoka, M.; Chang, T.H.; Tailor, P.; Sasaki, T.; Tashiro, M.; Kato, A.; Ozato, K. Virus infection triggers sumoylation of IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression. J. Biol. Chem. 2008, 283, 25660–25670. [Google Scholar]
- Ran, Y.; Liu, T.T.; Zhou, Q.; Li, S.; Mao, A.P.; Li, Y.; Liu, L.J.; Cheng, J.K.; Shu, H.B. SENP2 negatively regulates cellular antiviral response by desumoylating IRF3 and conditioning it for ubiquitination and degradation. J. Mol. Cell Biol. 2011, 3, 283–292. [Google Scholar]
- Boo, K.H.; Yang, J.S. Intrinsic cellular defenses against virus infection by antiviral type I interferon. Yonsei Med. J. 2010, 51, 9–17. [Google Scholar]
- Everett, R.D.; Chelbi-Alix, M.K. PML and PML nuclear bodies: Implications in antiviral defence. Biochimie 2007, 89, 819–830. [Google Scholar]
- McNab, F.W.; Rajsbaum, R.; Stoye, J.P.; O’Garra, A. Tripartite-motif proteins and innate immune regulation. Curr. Opin. Immunol. 2011, 23, 46–56. [Google Scholar]
- Stremlau, M.; Owens, C.M.; Perron, M.J.; Kiessling, M.; Autissier, P.; Sodroski, J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in old world monkeys. Nature 2004, 427, 848–853. [Google Scholar]
- Perron, M.J.; Stremlau, M.; Song, B.; Ulm, W.; Mulligan, R.C.; Sodroski, J. TRIM5alpha mediates the postentry block to n-tropic murine leukemia viruses in human cells. Proc. Natl. Acad. Sci. USA 2004, 101, 11827–11832. [Google Scholar]
- Arriagada, G.; Muntean, L.N.; Goff, S.P. SUMO-interacting motifs of human TRIM5 alpha are important for antiviral activity. PLoS Pathog. 2011, 7, e1002019. [Google Scholar]
- Geoffroy, M.C.; Chelbi-Alix, M.K. Role of promyelocytic leukemia protein in host antiviral defense. J. Interf. Cytokine Res. 2011, 31, 145–158. [Google Scholar]
- Kyratsous, C.A.; Silverstein, S.J. Components of nuclear domain 10 bodies regulate varicella-zoster virus replication. J. Virol. 2009, 83, 4262–4274. [Google Scholar]
- Djavani, M.; Rodas, J.; Lukashevich, I.S.; Horejsh, D.; Pandolfi, P.P.; Borden, K.L.B.; Salvato, M.S. Role of promyelocytic leukemia protein PML in the interferon sensitivity of lymphocytic choriomeningitis virus. J. Virol. 2001, 75, 6204–6208. [Google Scholar]
- El Mchichi, B.; Regad, T.; Maroui, M.A.; Rodriguez, M.S.; Aminev, A.; Gerbaud, S.; Escriou, N.; Dianoux, L.; Chelbi-Alix, M.K. Sumoylation promotes PML degradation during encephalomyocarditis virus infection. J. Virol. 2010, 84, 11634–11645. [Google Scholar]
- Blondel, D.; Regad, T.; Poisson, N.; Pavie, B.; Harper, F.; Pandolfi, P.P.; de The, H.; Chelbi-Alix, M.K. Rabies virus p and small p products interact directly with PML and reorganize PML nuclear bodies. Oncogene 2002, 21, 7957–7970. [Google Scholar]
- Bonilla, W.V.; Pinschewer, D.D.; Klenerman, P.; Rousson, V.; Gaboli, M.; Pandolfi, P.P.; Zinkernagel, M.; Salvato, M.S.; Hengartner, H. Effects of promyelocytic leukemia protein on virus-host balance. J. Virol. 2002, 76, 3810–3818. [Google Scholar]
- Tavalai, N.; Stamminger, T. Interplay between herpesvirus infection and host defense by PML nuclear bodies. Viruses 2009, 1, 1240–1264. [Google Scholar]
- Cuchet-Lourenco, D.; Boutell, C.; Lukashchuk, V.; Grant, K.; Sykes, A.; Murray, J.; Orr, A.; Everett, R.D. SUMO pathway dependent recruitment of cellular repressors to herpes simplex virus type 1 genomes. PLoS Pathog. 2011, 7, e1002123. [Google Scholar]
- Everett, R.D.; Parada, C.; Gripon, P.; Sirma, H.; Orr, A. Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100. J. Virol. 2008, 82, 2661–2672. [Google Scholar]
- Boutell, C.; Cuchet-Lourenco, D.; Vanni, E.; Orr, A.; Glass, M.; McFarlane, S.; Everett, R.D. A viral ubiquitin ligase has substrate preferential SUMO targeted ubiquitin ligase activity that counteracts intrinsic antiviral defence. PLoS Pathog. 2011, 7, e1002245. [Google Scholar]
- Kamitani, T.; Kito, K.; Nguyen, H.P.; Wada, H.; Fukuda-Kamitani, T.; Yeh, E.T. Identification of three major sentrinization sites in PML. J. Biol. Chem. 1998, 273, 26675–26682. [Google Scholar]
- Wang, L.; Oliver, S.L.; Sommer, M.; Rajamani, J.; Reichelt, M.; Arvin, A.M. Disruption of PML nuclear bodies is mediated by ORF61 SUMO-interacting motifs and required for varicella-zoster virus pathogenesis in skin. PLoS Pathog. 2011, 7, e1002157. [Google Scholar]
- Hotson, A.; Chosed, R.; Shu, H.J.; Orth, K.; Mudgett, M.B. Xanthomonas type III effector XopD targets SUMO-conjugated proteins in planta. Mol. Micro. 2003, 50, 377–389. [Google Scholar] [CrossRef]
- Roden, J.; Eardley, L.; Hotson, A.; Cao, Y.Y.; Mudgett, M.B. Characterization of the Xanthomonas Avrxv4 effector, a SUMO protease translocated into plant cells. Mol. Plant-Microbe Interact. 2004, 17, 633–643. [Google Scholar] [CrossRef]
- Kim, J.G.; Taylor, K.W.; Hotson, A.; Keegan, M.; Schmelz, E.A.; Mudgett, M.B. XopD SUMO protease affects host transcription, promotes pathogen growth, and delays symptom development in Xanthomonas-infected tomato leaves. Plant Cell 2008, 20, 1915–1929. [Google Scholar] [CrossRef]
- Chang, P.C.; Izumiya, Y.; Wu, C.Y.; Fitzgerald, L.D.; Campbell, M.; Ellison, T.J.; Lam, K.S.; Luciw, P.A.; Kung, H.J. Kaposi’s sarcoma-associated herpesvirus (KSHV) encodes a SUMO E3 ligase that is SIM-dependent and SUMO-2/3-specific. J. Biol. Chem. 2010, 285, 5266–5273. [Google Scholar]
- Pennella, M.A.; Liu, Y.; Woo, J.L.; Kim, C.A.; Berk, A.J. Adenovirus E1B 55-kilodalton protein is a p53-SUMO1 E3 ligase that represses p53 and stimulates its nuclear export through interactions with promyelocytic leukemia nuclear bodies. J. Virol. 2010, 84, 12210–12225. [Google Scholar]
- Muller, S.; Dobner, T. The adenovirus E1B-55k oncoprotein induces SUMO modification of p53. Cell Cycle 2008, 7, 754–758. [Google Scholar]
- Izumiya, Y.; Ellison, T.J.; Yeh, E.T.H.; Jung, J.U.; Luciw, P.A.; Kung, H.J. Kaposi’s sarcoma-associated herpesvirus K-bZIP represses gene transcription via SUMO modification. J. Virol. 2005, 79, 9912–9925. [Google Scholar]
- Izumiya, Y.; Izumiya, C.; Van Geelen, A.; Wang, D.H.; Lam, K.S.; Luciw, P.A.; Kung, H.J. Kaposi’s sarcoma-associated herpesvirus-encoded protein kinase and its interaction with K-bZIP. J. Virol. 2007, 81, 1072–1082. [Google Scholar]
- Perry, J.J.P.; Tainer, J.A.; Boddy, M.N. A SIM-ultaneous role for SUMO and ubiquitin. Trends Biochem. Sci. 2008, 33, 201–208. [Google Scholar]
- Viswanathan, K.; Fruh, K.; DeFilippis, V. Viral hijacking of the host ubiquitin system to evade interferon responses. Curr. Opin. Microbiol. 2010, 13, 517–523. [Google Scholar]
- Boggio, R.; Colombo, R.; Hay, R.T.; Draetta, G.F.; Chiocca, S. A mechanism for inhibiting the SUMO pathway. Mol. Cell 2004, 16, 549–561. [Google Scholar]
- Glotzer, J.B.; Saltik, M.; Chiocca, S.; Michou, A.I.; Moseley, P.; Cotten, M. Activation of heat-shock response by an adenovirus is essential for virus replication. Nature 2000, 407, 207–211. [Google Scholar]
- Colombo, R.; Boggio, R.; Seiser, C.; Draetta, G.F.; Chiocca, S. The adenovirus protein GAM1 interferes with sumoylation of histone deacetylase 1. EMBO Rep. 2002, 3, 1062–1068. [Google Scholar]
- Boggio, R.; Passafaro, A.; Chiocca, S. Targeting SUMO E1 to ubiquitin ligases - a viral strategy to counteract sumoylation. J. Biol. Chem. 2007, 282, 15376–15382. [Google Scholar]
- Garcia-Dominguez, M.; Reyes, J.C. SUMO association with repressor complexes, emerging routes for transcriptional control. Biochim. Biophys. Acta-Gene Reg. Mech. 2009, 1789, 451–459. [Google Scholar]
- Boggio, R.; Chiocca, S. GAM1 and the SUMO pathway. Cell Cycle 2005, 4, 533–535. [Google Scholar]
- Bischof, O.; Schwamborn, K.; Martin, N.; Werner, A.; Sustmann, C.; Grosschedl, R.; Dejean, A. The E3 SUMO ligase PIASy is a regulator of cellular senescence and apoptosis. Mol. Cell 2006, 22, 783–794. [Google Scholar]
- Chang, T.H.; Kubota, T.; Matsuoka, M.; Jones, S.; Bradfute, S.B.; Bray, M.; Ozato, K. Ebola zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog. 2009, 5, e1000493. [Google Scholar]
- Ribet, D.; Hamon, M.; Gouin, E.; Nahori, M.A.; Impens, F.; Neyret-Kahn, H.; Gevaert, K.; Vandekerckhove, J.; Dejean, A.; Cossart, P. Listeria monocytogenes impairs sumoylation for efficient infection. Nature 2010, 464, 1192–1195. [Google Scholar]
- Heaton, P.R.; Deyrieux, A.F.; Bian, X.L.; Wilson, V.G. HPV E6 proteins target Ubc9, the SUMO conjugating enzyme. Virus Res. 2011, 158, 199–208. [Google Scholar]
- Howie, H.L.; Katzenellenbogen, R.A.; Galloway, D.A. Papillomavirus E6 proteins. Virology 2009, 384, 324–334. [Google Scholar]
- Marusic, M.B.; Mencin, N.; Licen, M.; Banks, L.; Grm, H.S.T. Modification of human papillomavirus minor capsid protein L2 by sumoylation. J. Virol. 2010, 84, 11585–11589. [Google Scholar]
- Bentz, G.L.; Whitehurst, C.B.; Pagano, J.S. Epstein-barr virus latent membrane protein 1 (LMP1) c-terminal-activating region 3 contributes to LMP1-mediated cellular migration via its interaction with Ubc9. J. Virol. 2011, 85, 10144–10153. [Google Scholar]
- Pal, S.; Santos, A.; Rosas, J.M.; Ortiz-Guzman, J.; Rosas-Acosta, G. Influenza A virus interacts extensively with the cellular sumoylation system during infection. Virus Res. 2011, 158, 12–27. [Google Scholar]
- Yousef, A.F.; Fonseca, G.J.; Pelka, P.; Ablack, J.N.G.; Walsh, C.; Dick, F.A.; Bazett-Jones, D.P.; Shaw, G.S.; Mymryk, J.S. Identification of a molecular recognition feature in the E1A oncoprotein that binds the SUMO conjugase Ubc9 and likely interferes with polysumoylation. Oncogene 2010, 29, 4693–4704. [Google Scholar]
- Knipscheer, P.; Flotho, A.; Klug, H.; Olsen, J.V.; van Dijk, W.J.; Fish, A.; Johnson, E.S.; Mann, M.; Sixma, T.K.; Pichler, A. Ubc9 sumoylation regulates SUMO target discrimination. Mol. Cell 2008, 31, 371–382. [Google Scholar]
- Gomes, R.; Guerra-Sa, R.; Arruda, E. Coxsackievirus L35 induced apoptosis of HeLa cells: Effects on p53 and SUMO. Virology 2010, 396, 256–263. [Google Scholar]
- Ledl, A.; Schmidt, D.; Muller, S. Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor. Oncogene 2005, 24, 3810–3818. [Google Scholar]
- Macaluso, M.; Montanari, M.; Giordano, A. Rb family proteins as modulators of gene expression and new aspects regarding the interaction with chromatin remodeling enzymes. Oncogene 2006, 25, 5263–5267. [Google Scholar]
- Chang, P.C.; Fitzgerald, L.D.; Van Geelen, A.; Izumiya, Y.; Ellison, T.J.; Wang, D.H.; Ann, D.K.; Luciw, P.A.; Kung, H.J. Kruppel-associated box domain-associated protein-1 as a latency regulator for Kaposi’s sarcoma-associated herpesvirus and its modulation by the viral protein kinase. Cancer Res 2009, 69, 5681–5689. [Google Scholar]
- Schultz, D.C.; Ayyanathan, K.; Negorev, D.; Maul, G.G.; Rauscher, F.J., 3rd. Setdb1: A novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to Hp1-mediated silencing of euchromatic genes by Krab zinc-finger proteins. Genes Dev. 2002, 16, 919–932. [Google Scholar] [CrossRef]
- Ivanov, A.V.; Peng, H.; Yurchenko, V.; Yap, K.L.; Negorev, D.G.; Schultz, D.C.; Psulkowski, E.; Fredericks, W.J.; White, D.E.; Maul, G.G.; et al. Phd domain-mediated E3 ligase activity directs intramolecular sumoylation of an adjacent bromodomain required for gene silencing. Mol.Cell 2007, 28, 823–837. [Google Scholar] [CrossRef]
- Li, X.; Lee, Y.K.; Jeng, J.C.; Yen, Y.; Schultz, D.C.; Shih, H.M.; Ann, D.K. Role for KAP1 serine 824 phosphorylation and sumoylation/desumoylation switch in regulating KAP1-mediated transcriptional repression. J. Biol. Chem. 2007, 282, 36177–36189. [Google Scholar]
- Maul, G.G.; Negorev, D.; Bell, P.; Ishov, A.M. Properties and assembly mechanisms of ND10, PML bodies, or PODs [review]. J. Struct. Biol. 2000, 129, 278–287. [Google Scholar] [CrossRef]
- Ishov, A.M.; Sotnikov, A.G.; Negorev, D.; Vladimirova, O.V.; Neff, N.; Kamitani, T.; Yeh, E.T.H.; Strauss, J.F.; Maul, G.G. PML is critical for ND10 formation and recruits the PML-interacting protein Daxx to this nuclear structure when modified by SUMO-1. J. Cell. Biol. 1999, 147, 221–233. [Google Scholar]
- Adamson, A.L.; Kenney, S. Epstein-Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J. Virol. 2001, 75, 2388–2399. [Google Scholar]
- Marcos-Villar, L.; Campagna, M.; Lopitz-Otsoa, F.; Gallego, P.; Gonzalez-Santamaria, J.; Gonzalez, D.; Rodriguez, M.S.; Rivas, C. Covalent modification by SUMO is required for efficient disruption of PML oncogenic domains by Kaposi’s sarcoma-associated herpesvirus latent protein LANA2. J. Gen. Virol. 2011, 92, 188–194. [Google Scholar]
- Ahn, J.H.; Hayward, G.S. The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells. J. Virol. 1997, 71, 4599–4613. [Google Scholar]
- Muller, S.; Dejean, A. Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. J. Virol. 1999, 73, 5137–5143. [Google Scholar]
- Hagemeier, S.R.; Dickerson, S.J.; Meng, Q.; Yu, X.M.; Mertz, J.E.; Kenney, S.C. Sumoylation of the Epstein-Barr virus BZLF1 protein inhibits its transcriptional activity and is regulated by the virus-encoded protein kinase. J. Virol. 2010, 84, 4383–4394. [Google Scholar]
- Marcos-Villar, L.; Lopitz-Otsoa, F.; Gallego, P.; Munoz-Fontela, C.; Gonzalez-Santamaria, J.; Campagna, M.; Shou-Jiang, G.; Rodriguez, M.S.; Rivas, C. Kaposi’s sarcoma-associated herpesvirus protein LANA2 disrupts PML oncogenic domains and inhibits PML-mediated transcriptional repression of the survivin gene. J. Virol. 2009, 83, 8849–8858. [Google Scholar]
- Lallemand-Breitenbach, V.; Jeanne, M.; Benhenda, S.; Nasr, R.; Lei, M.; Peres, L.; Zhou, J.; Zhu, J.; Raught, B.; de The, H. Arsenic degrades PML or PML-RAR alpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell Biol. 2008, 10, 547–555. [Google Scholar]
- Xu, Y.X.; Ahn, J.H.; Cheng, M.F.; Ap Rhys, C.M.; Chiou, C.J.; Zong, J.H.; Matunis, M.J.; Hayward, G.S. Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression. J. Virol. 2001, 75, 10683–10695. [Google Scholar]
- Boutell, C.; Orr, A.; Everett, R.D. PML residue lysine 160 is required for the degradation of PML induced by herpes simplex virus type 1 regulatory protein ICP0. J. Virol. 2003, 77, 8686–8694. [Google Scholar]
- Lee, H.R.; Kim, D.J.; Lee, J.M.; Choi, C.Y.; Ahn, B.Y.; Hayward, G.S.; Ahn, J.H. Ability of the human cytomegalovirus IE1 protein to modulate sumoylation of PML correlates with its functional activities in transcriptional regulation and infectivity in cultured fibroblast cells. J. Virol. 2004, 78, 6527–6542. [Google Scholar]
- Kang, H.; Kim, E.T.; Lee, H.R.; Park, J.J.; Go, Y.Y.; Choi, C.Y.; Ahn, J.H. Inhibition of SUMO-independent PML oligomerization by the human cytomegalovirus IE1 protein. J. Gen. Virol. 2006, 87, 2181–2190. [Google Scholar]
- Hofmann, H.; Floss, S.; Stamminger, T. Covalent modification of the transactivator protein IE2-p86 of human cytomegalovirus by conjugation to the ubiquitin-homologous proteins SUMO-1 and HSMT3b. J. Virol. 2000, 74, 2510–2524. [Google Scholar]
- Ahn, J.-H.; Xu, Y.; Jang, W.-J.; Matunis, M.J.; Hayward, G.S. Evaluation of interactions of human cytomegalovirus immediate-early IE2 regulatory protein with small ubiquitin-like modifiers and their conjugation enzyme Ubc9. J. Virol. 2001, 75, 3859–3872. [Google Scholar]
- Lee, J.M.; Kang, H.J.; Lee, H.R.; Choi, C.Y.; Jang, W.J.; Ahn, J.H. PIAS1 enhances SUMO-1 modification and the transactivation activity of the major immediate-early IE2 protein of human cytomegalovirus. FEBS Lett. 2003, 555, 322–328. [Google Scholar]
- Kim, E.T.; Kim, Y.E.; Huh, Y.H.; Ahn, J.H. Role of noncovalent SUMO binding by the human cytomegalovirus IE2 transactivator in lytic growth. J. Virol. 2010, 84, 8111–8123. [Google Scholar]
- Berndt, A.; Hofmann-Winkler, H.; Tavalai, N.; Hahn, G.; Stamminger, T. Importance of covalent and noncovalent SUMO interactions with the major human cytomegalovirus transactivator IE2p86 for viral infection. J. Virol. 2009, 83, 12881–12894. [Google Scholar]
- Sourvinos, G.; Tavalai, N.; Berndt, A.; Spandidos, D.A.; Stamminger, T. Recruitment of human cytomegalovirus immediate-early 2 protein onto parental viral genomes in association with ND10 in live-infected cells. J. Virol. 2007, 81, 10123–10136. [Google Scholar]
- Sternsdorf, T.; Jensen, K.; Will, H. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J. Cell Biol. 1997, 139, 1621–1634. [Google Scholar]
- Jang, M.S.; Ryu, S.W.; Kim, E. Modification of Daxx by small ubiquitin-related modifier-1. Biochem. Biophys. Res. Commun. 2002, 295, 495–500. [Google Scholar]
- Parkinson, J.; Everett, R.D. Alphaherpesvirus proteins related to herpes simplex virus type 1 ICP0 affect cellular structures and proteins. J. Virol. 2000, 74, 10006–10017. [Google Scholar]
- Hwang, J.; Kalejta, R.F. Human cytomegalovirus protein pp71 induces Daxx sumoylation. J. Virol. 2009, 83, 6591–6598. [Google Scholar]
- Zamborlini, A.; Coiffic, A.; Beauclair, G.; Delelis, O.; Paris, J.; Koh, Y.; Magne, F.; Giron, M.L.; Tobaly-Tapiero, J.; Deprez, E.; et al. Impairment of human immunodeficiency virus type-1 integrase sumoylation correlates with an early replication defect. J. Biol. Chem. 2011, 286, 21013–21022. [Google Scholar]
- Endter, C.; Kzhyshkowska, J.; Stauber, R.; Dobner, T. SUMO-1 modification required for transformation by adenovirus type 5 early region 1B 55-kDa oncoprotein. Proc. Natl. Acad. Sci. USA 2001, 98, 11312–11317. [Google Scholar]
- Weger, S.; Hammer, E.; Heilbronn, R. SUMO-1 modification regulates the protein stability of the large regulatory protein rep78 of adeno associated virus type 2 (AAV-2). Virology 2004, 330, 284–294. [Google Scholar]
- Lamsoul, I.; Lodewick, J.; Lebrun, S.; Brasseur, R.; Burny, A.; Gaynor, R.B.; Bex, F. Exclusive ubiquitination and sumoylation on overlapping lysine residues mediate NF-kappa B activation by the human T-cell leukemia virus Tax oncoprotein. Mol. Cell. Biol. 2005, 25, 10391–10406. [Google Scholar]
- Yueh, A.; Leung, J.; Bhattacharyya, S.; Perrone, L.A.; Pu, S.Y.; Goff, S.P. Interaction of moloney murine leukemia virus capsid with Ubc9 and PIASy mediates SUMO-1 addition required early in infection. J. Virol. 2006, 80, 342–352. [Google Scholar]
- Gonzalez-Santamaria, J.; Campagna, M.; Garcia, M.A.; Marcos-Villar, L.; Gonzalez, D.; Gallego, P.; Lopitz-Otsoa, F.; Guerra, S.; Rodriguez, M.S.; Esteban, M.; et al. Regulation of vaccinia virus E3 protein by small ubiquitin-like modifier proteins. J. Virol. 2011, 85, 12890–12900. [Google Scholar]
- Chang, L.K.; Lee, Y.H.; Cheng, T.S.; Hong, Y.R.; Lu, P.J.; Wang, J.J.; Wang, W.H.; Kuo, C.W.; Li, S.S.L.; Liu, S.T. Post-translational modification of Rta of Epstein-Barr virus by SUMO-1. J. Biol. Chem. 2004, 279, 38803–38812. [Google Scholar]
- Rosendorff, A.; Illanes, D.; David, G.; Lin, J.; Kieff, E.; Johannsen, E. EBNA3c coactivation with EBNA2 requires a SUMO homology domain. J. Virol. 2004, 78, 367–377. [Google Scholar]
- Tseng, C.H.; Cheng, T.S.; Shu, C.Y.; Jeng, K.S.; Lai, M.M.C. Modification of small hepatitis delta virus antigen by SUMO protein. J. Virol. 2010, 84, 918–927. [Google Scholar]
- Rangasamy, D.; Wilson, V.G. Bovine papillomavirus E1 protein is sumoylated by the host cell Ubc9 protein. J. Biol. Chem. 2000, 275, 30487–30495. [Google Scholar]
- Gravel, A.; Gosselin, J.; Flamand, L. Human herpesvirus 6 immediate-early 1 protein is a sumoylated nuclear phosphoprotein colocalizing with promyelocytic leukemia protein-associated nuclear bodies. J. Biol. Chem. 2002, 277, 19679–19687. [Google Scholar]
- Stanton, R.; Fox, J.D.; Caswell, R.; Sherratt, E.; Wilkinson, G.W.G. Analysis of the human herpesvirus-6 immediate-early 1 protein. J. Gen. Virol. 2002, 83, 2811–2820. [Google Scholar]
- Wu, Y.C.; Roark, A.A.; Bian, X.L.; Wilson, V.G. Modification of papillomavirus E2 proteins by the small ubiquitin-like modifier family members (SUMOs). Virology 2008, 378, 329–338. [Google Scholar]
- Li, F.Q.S.; Xiao, H.; Tam, J.P.; Liu, D.X. Sumoylation of the nucleocapsid protein of severe acute respiratory syndrome coronavirus. FEBS Lett. 2005, 579, 2387–2396. [Google Scholar]
- Gurer, C.; Berthoux, L.; Luban, J. Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1. J. Virol. 2005, 79, 910–917. [Google Scholar]
- Sun, D.Y.; Xu, P.; He, B. Sumoylation of the P protein at K254 plays an important role in growth of parainfluenza virus 5. J. Virol. 2011, 85, 10261–10268. [Google Scholar]
- Chen, S.C.; Chang, L.Y.; Wang, Y.W.; Chen, Y.C.; Weng, K.F.; Shih, S.R.; Shih, H.M. Sumoylation-promoted enterovirus 71 3C degradation correlates with a reduction in viral replication and cell apoptosis. J. Biol. Chem. 2011, 286, 31373–31384. [Google Scholar]
- Palacios, S.; Perez, L.H.; Welsch, S.; Schleich, S.; Chmielarska, K.; Melchior, F.; Locker, J.K. Quantitative SUMO-1 modification of a vaccinia virus protein is required for its specific localization and prevents its self-association. Mol. Biol. Cell 2005, 16, 2822–2835. [Google Scholar]
- Stallings, C.L.; Silverstein, S.J. Posttranslational modification and cell type-specific degradation of varicella-zoster virus ORF29p. J. Virol. 2006, 80, 10836–10846. [Google Scholar]
- Pal, S.; Rosas, J.M.; Rosas-Acosta, G. Identification of the non-structural influenza A viral protein NS1a as a bona fide target of the small ubiquitin-like modifier by the use of dicistronic expression constructs. J. Virol. Meth. 2010, 163, 498–504. [Google Scholar]
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license ( http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Wilson, V.G. Sumoylation at the Host-Pathogen Interface. Biomolecules 2012, 2, 203-227. https://doi.org/10.3390/biom2020203
Wilson VG. Sumoylation at the Host-Pathogen Interface. Biomolecules. 2012; 2(2):203-227. https://doi.org/10.3390/biom2020203
Chicago/Turabian StyleWilson, Van G. 2012. "Sumoylation at the Host-Pathogen Interface" Biomolecules 2, no. 2: 203-227. https://doi.org/10.3390/biom2020203